MELANOTAN 1

MELANOTAN 1

$42.00

Melanotan

$42.00

Add to cart
Buy Now
SKU: PEPT-MT1-005 Category: Tag: Brand:

PEPT-MT1-005


MELANOTAN 1

Melanotan 1 (MT-1), also known as afamelanotide, is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) designed exclusively for laboratory research. This linear heptapeptide (Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) acts as a potent, selective melanocortin-1 receptor (MC1R) agonist.

Used primarily in preclinical dermatological and photobiology research, Melanotan 1 stimulates eumelanin production without significant activation of other melanocortin receptors. This selectivity makes it a valuable tool for studying UV-independent melanogenesis, DNA repair pathways, and photoprotection mechanisms. Each lyophilized vial is synthesized to ≥99% purity, verified by independent HPLC and mass spectrometry.


Key Features

  • Ultra-High Purity: ≥99% confirmed by third-party HPLC analysis

  • MC1R-Selective: Minimal cross-reactivity with MC3R, MC4R, or MC5R

  • UV-Independent Melanogenesis: Stimulates eumelanin production without UV exposure

  • Stable Lyophilized Format: Easy reconstitution for cell culture or preclinical research

  • Research Use Only: Not for human consumption, cosmetic use, or clinical application


Specifications

Specification Detail
Molecular Formula C₇₈H₁₁₁N₂₁O₁₉
Molecular Weight 1,646.85 g/mol
Sequence Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂
Purity ≥99% (HPLC)
Appearance White lyophilized powder
Storage (Lyophilized) -20°C, protected from light and moisture
Storage (Reconstituted) 2-8°C for up to 14 days; aliquot for longer storage

Research Applications

Melanotan 1 is widely used in preclinical studies investigating:

  • Photoprotection: Studying melanin-mediated UV radiation shielding and DNA damage repair

  • Erythropoietic Protoporphyria (EPP) Models: Light tolerance and oxidative stress reduction

  • Melanoma Research: MC1R signaling, pigmentation pathways, and tumor biology

  • Dermatological Inflammation: Contact hypersensitivity and sunburn cell formation models

Typical Research Parameters

Parameter Recommendation
Reconstitution Sterile water or bacteriostatic water
In Vitro Concentration 0.1–10 µM (melanocyte cultures)
Preclinical Dosage (Rodent) 25–100 µg/kg, subcutaneous
Onset of Melanogenesis (In Vivo) 7–14 days with daily administration

Note: These are references for laboratory protocol design only, not medical dosing instructions.


Mechanism of Action

Melanotan 1 exerts its research-documented effects through:

  • MC1R Activation: Stimulates adenylate cyclase → cAMP elevation → PKA activation

  • Eumelanin Upregulation: Increases tyrosinase, TRP-1, and TRP-2 expression

  • DNA Repair Enhancement: Promotes nucleotide excision repair (NER) pathways

  • Anti-Inflammatory Effects: Reduces UV-induced cytokine release (TNF-α, IL-6)


Comparison: Melanotan 1 vs. Melanotan 2

Feature Melanotan 1 (MT-1) Melanotan 2 (MT-2)
Structure Linear heptapeptide Cyclic lactam
MC1R Selectivity High Moderate
MC3R/MC4R Activity Minimal Significant (appetite/libido effects)
Half-Life (Research Models) ~1–2 hours ~30+ minutes (longer in some models)
Primary Research Focus Photoprotection, EPP Pigmentation + appetite studies

Quality Assurance

This Melanotan 1 product undergoes rigorous quality control, including:

  • HPLC Purity Verification: ≥99% with full chromatographic trace

  • Mass Spectrometry Confirmation: Molecular weight validated (ESI-MS)

  • Endotoxin Testing: <1 EU/mg for cell culture compatibility

  • Batch Tracking: Certificate of Analysis available for each lot


Shipping & Storage

  • Shipping: Ambient with cold pack (2–8°C recommended during transit)

  • Upon Arrival: Store lyophilized material at -20°C immediately

  • Avoid Freeze-Thaw: Aliquot reconstituted peptide to prevent degradation

  • Shelf Life: 18 months from the manufacture date when stored as directed at -20°C

Reviews

There are no reviews yet.

Be the first to review “MELANOTAN 1”

Your email address will not be published. Required fields are marked *